<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01534247</url>
  </required_header>
  <id_info>
    <org_study_id>D4280C00012</org_study_id>
    <nct_id>NCT01534247</nct_id>
  </id_info>
  <brief_title>A Study to Assess the Levels of CAZ-AVI and Metronidazole in the Blood When Given Together and Separately</brief_title>
  <official_title>A Phase I, Open-Label, 3-way Crossover, Pharmacokinetic and Drug-Drug Interaction Study of Ceftazidime Avibactam (CAZ-AVI) and Metronidazole When Administered Alone and in Combination in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Forest Laboratories</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Pfizer</source>
  <brief_summary>
    <textblock>
      The purpose of the study is to assess whether there is any pharmacokinetic interactions
      between CAZ-AVI and metronidazole.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A Phase I, Open-Label, 3-way Crossover, Pharmacokinetic and Drug-Drug Interaction Study of
      ceftazidime avibactam (CAZ-AVI) and Metronidazole when Administered Alone and in Combination
      in Healthy Subjects
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2012</start_date>
  <completion_date type="Actual">July 2012</completion_date>
  <primary_completion_date type="Actual">July 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Profile of pharmacokinetic of ceftazidime, avibactam and metronidazole when administering CAZ-AVI plus metronidazole in combination compared to administration of individual components</measure>
    <time_frame>CAZ-AVI: pre-dose, 0.5, 1, 1.5, 2, 2.25, 2.5, 2.75, 3, 4, 5, 7, 11, 23, 73, 73.5, 74, 74.5, 75, 75.25, 75.5, 75.75, 76, 77, 78, 80, 84 and 95 hours post-dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Profile of pharmacokinetic of ceftazidime, avibactam and metronidazole when administering CAZ-AVI plus metronidazole in combination compared to administration of individual components</measure>
    <time_frame>Metronidazole: pre-dose, 0.5, 1, 1.25, 1.5, 2, 3, 4, 6, 8, 12, 24, 72, 72.5, 73, 73.25, 73.5, 74, 75, 76, 78, 80, 84 and 96 hours post-dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Profile of pharmacokinetic of ceftazidime, avibactam and metronidazole when administering CAZ-AVI plus metronidazole in combination compared to administration of individual components</measure>
    <time_frame>CAZ-AVI and metronidazole: pre-dose, 0.5, 1, 1.25, 1.5, 2.5, 3, 3.25, 3.5, 3.75, 4, 5, 6, 8, 12, 24, 72, 72.5, 73, 73.25, 73.5, 74, 74.5, 75, 75.25, 75.5, 75.75, 76, 77, 78, 80, 84 and 96 hours post-dose</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To assess safety and tolerability of CAZ-AVI and metronidazole when administered as a 2- and 1-hour infusion, respectively, every 8 hours by assessment of adverse events, lab, vital signs, ECG, physical examination</measure>
    <time_frame>Screening up to 26 days after first dose</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">28</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>CAZAVI</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CAZ-AVI (2000 mg ceftazidime/500 mg avibactam)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Metronidazole</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Metronidazole (500 mg)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CAZAVI+metronidazole</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>CAZ-AVI (2000mg ceftazidime/500 mg avibactam) + metronidazole (500 mg)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CAZ-AVI</intervention_name>
    <description>Infusion</description>
    <arm_group_label>CAZAVI</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>metronidazole</intervention_name>
    <description>Infusion</description>
    <arm_group_label>Metronidazole</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CAZ-AVI + metronidazole</intervention_name>
    <description>Infusion</description>
    <arm_group_label>CAZAVI+metronidazole</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Provision of signed and dated, written informed consent prior to any study-specific
             procedures.

          -  Healthy male and female subjects aged 18 to 50 years (inclusive) with suitable veins
             for cannulation or repeated venipuncture; female subjects must be post menopausal or
             surgically sterile.

          -  Male subjects should be willing to use barrier contraception ie, condoms, from the
             first day of the investigational product administration until 3 months after the last
             administration of the investigational product.

          -  Have a body mass index (BMI) between 19 and 30 kg/m2

          -  Be able to understand and willing to comply with study procedures, restrictions, and
             requirements, as judged by the Investigator

        Exclusion Criteria:

          -  History of any clinically significant disease or disorder which, in the opinion of the
             Investigator, may either put the subject at risk because of participation in the
             study, or influence the results or the subject's ability to participate in the study

          -  History or presence of gastrointestinal, hepatic or renal disease, or any other
             condition known to interfere with absorption, distribution, metabolism, or excretion
             of drugs

          -  Known history of serious allergy, hypersensitivity (eg, anaphylaxis), or any serious
             reaction to carbapenem or cephalosporin antibiotics or other beta-actam antibiotics or
             any other investigational product to be administered as part of the study

          -  Any clinically significant illness, medical/surgical procedure or trauma within 4
             weeks prior to the first administration of investigational product Any clinically
             significant abnormalities in physical examination, ECG, clinical chemistry,
             haematology, or urinalysis results, as judged by the Investigator
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mirjana Kujacic, MD</last_name>
    <role>Study Chair</role>
    <affiliation>AstraZenecaMolndal Sweden</affiliation>
  </overall_official>
  <overall_official>
    <last_name>David Mathews, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>QuintilesOverland Park, US</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Paul Newell</last_name>
    <role>Study Director</role>
    <affiliation>Astrazeneca Alderly UK</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research site</name>
      <address>
        <city>Overland Park</city>
        <state>Kansas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_MED_7111&amp;studyid=1458&amp;filename=Redaction%20of%20D4280C00012%20Protocol.pdf</url>
    <description>Redaction of D4280C00012 Protocol</description>
  </link>
  <reference>
    <citation>Das S, Li J, Armstrong J, Learoyd M, Edeki T. Randomized pharmacokinetic and drug-drug interaction studies of ceftazidime, avibactam, and metronidazole in healthy subjects. Pharmacol Res Perspect. 2015 Oct;3(5):e00172. doi: 10.1002/prp2.172. Epub 2015 Aug 25.</citation>
    <PMID>26516584</PMID>
  </reference>
  <verification_date>September 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 9, 2012</study_first_submitted>
  <study_first_submitted_qc>February 13, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 16, 2012</study_first_posted>
  <last_update_submitted>September 1, 2017</last_update_submitted>
  <last_update_submitted_qc>September 1, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 5, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Phase I</keyword>
  <keyword>drug to drug</keyword>
  <keyword>CAZ-AVI</keyword>
  <keyword>Healthy volunteer</keyword>
  <keyword>pharmacokinetics</keyword>
  <keyword>open label</keyword>
  <keyword>metronidazole</keyword>
  <keyword>safety</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Avibactam</mesh_term>
    <mesh_term>Metronidazole</mesh_term>
    <mesh_term>Ceftazidime</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

